Raltitrexed

CHEMBL225071 Phase 4 已批准 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

458.5 g/mol

LogP

1.4

Phase

4

Raltitrexed is a quinazoline folate analog that directly and specifically inhibits thymidylate synthase (TS) after intracellular polyglutamation, thereby depleting thymidine monophosphate and disrupting DNA synthesis and repair in rapidly dividing cells. It is used for the treatment of advanced colorectal cancer and has been investigated in mesothelioma and other malignancies.

分子量

458.5000 g/mol

LogP

1.40

TPSA

177.00 Å²

Lipinski 五规则

符合

治疗领域

Pancreatic Cancer Cardiovascular Disease Respiratory Disease Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Infectious Disease Gastroesophageal Reflux Disease Inflammatory Bowel Disease Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

二维结构

SVG PNG

Cite this structure

Embed this structure

SMILES

Cc1nc(=O)c2cc(CN(C)c3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)s3)ccc2[nH]1

InChI

InChI=1S/C21H22N4O6S/c1-11-22-14-4-3-12(9-13(14)19(28)23-11)10-25(2)17-7-6-16(32-17)20(29)24-15(21(30)31)5-8-18(26)27/h3-4,6-7,9,15H,5,8,10H2,1-2H3,(H,24,29)(H,26,27)(H,30,31)(H,22,23,28)/t15-/m0/s1

Molecular Formula

C21H22N4O6S

HBD / HBA

4 / 9

可旋转键数

9

重原子数

32

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

Raltitrexed is a quinazoline folate analog that directly and specifically inhibits thymidylate synthase (TS) after intracellular polyglutamation, thereby depleting thymidine monophosphate and disrupting DNA synthesis and repair in rapidly dividing cells. It is used for the treatment of advanced colorectal cancer and has been investigated in mesothelioma and other malignancies.

Yes, Raltitrexed is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL225071. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 135400182. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

正在寻找患者友好型信息？

Raltitrexed 在 PillFYI 上

结构

快速数据

分子式: C21H22N4O6S

外部链接

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.